WO2007048059A3 - Method of treating clostridium difficile-associated diarrhea - Google Patents

Method of treating clostridium difficile-associated diarrhea Download PDF

Info

Publication number
WO2007048059A3
WO2007048059A3 PCT/US2006/041436 US2006041436W WO2007048059A3 WO 2007048059 A3 WO2007048059 A3 WO 2007048059A3 US 2006041436 W US2006041436 W US 2006041436W WO 2007048059 A3 WO2007048059 A3 WO 2007048059A3
Authority
WO
WIPO (PCT)
Prior art keywords
clostridium difficile
associated diarrhea
treating clostridium
species
treating
Prior art date
Application number
PCT/US2006/041436
Other languages
French (fr)
Other versions
WO2007048059A2 (en
Inventor
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Original Assignee
Optimer Pharmaceuticals Inc
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals Inc, Pamela Sears, Youe-Kong Shue, Starr Louise Miller-Shangle, Robert Brian Walsh, Farah Babakhani, Yu-Hung Chiu, Alex Romero, Sherwood Gorbach, Thomas John Louie filed Critical Optimer Pharmaceuticals Inc
Priority to EP06826544A priority Critical patent/EP1940417A4/en
Priority to JP2008536608A priority patent/JP2009512691A/en
Priority to CN2006800479861A priority patent/CN101340919B/en
Priority to AU2006304868A priority patent/AU2006304868B2/en
Priority to KR1020087012193A priority patent/KR101399621B1/en
Priority to CA2626698A priority patent/CA2626698C/en
Publication of WO2007048059A2 publication Critical patent/WO2007048059A2/en
Publication of WO2007048059A3 publication Critical patent/WO2007048059A3/en
Priority to HK09105230.0A priority patent/HK1126410A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a disease or disorder caused by the presence of a bacterium selected from the group consisting Clostridium species, Staphylococcus species, Enterococcus species and combinations thereof comprising administering to a patient in need an effective amount of a mixture, which comprises tiacumicin B, lipiarmycin A4, and at least one of other macrocyclic compounds .
PCT/US2006/041436 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea WO2007048059A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06826544A EP1940417A4 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea
JP2008536608A JP2009512691A (en) 2005-10-21 2006-10-23 Treatment of Clostridium difficile-related diarrhea
CN2006800479861A CN101340919B (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea
AU2006304868A AU2006304868B2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea
KR1020087012193A KR101399621B1 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea
CA2626698A CA2626698C (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea
HK09105230.0A HK1126410A1 (en) 2005-10-21 2009-06-10 Method of treating clostridium difficile-associated diarrhea

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12

Publications (2)

Publication Number Publication Date
WO2007048059A2 WO2007048059A2 (en) 2007-04-26
WO2007048059A3 true WO2007048059A3 (en) 2007-05-31

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041436 WO2007048059A2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Country Status (8)

Country Link
EP (1) EP1940417A4 (en)
JP (1) JP2009512691A (en)
KR (1) KR101399621B1 (en)
CN (2) CN101340919B (en)
AU (1) AU2006304868B2 (en)
CA (1) CA2626698C (en)
HK (1) HK1126410A1 (en)
WO (1) WO2007048059A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (en) 2007-11-27 2016-03-01 默沙東藥廠 Antibiotic macrocycle compounds and methods of manufacture and use thereof
JO3464B1 (en) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd Compositions of Tiacumicin Compounds
CN104846044B (en) * 2014-02-17 2019-02-01 上海医药工业研究院 A kind of fermentation medium improving feldamycin yield
CN105237599B (en) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 New Year Amycin A4 crystal and preparation method thereof
CN107714713B (en) * 2017-10-25 2020-05-26 中山大学 Application of tiacumicin derivative in preparation of medicine for treating related diseases and/or symptoms caused by dengue virus infection
CN107970253B (en) * 2017-10-25 2020-05-26 中山大学 Application of tiacumicin derivative in preparation of medicine for treating related diseases and/or symptoms caused by Zika virus infection
WO2019236806A1 (en) * 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
KR100972542B1 (en) * 2002-07-29 2010-07-28 옵티머 파마슈티칼즈, 인코포레이티드 Tiacumicin production
US20070173462A1 (en) * 2004-05-14 2007-07-26 Optimer Pharmaceuticals, Inc. Treatment of diseases associated with the use of antibiotics
BRPI0519890A2 (en) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc 18-element macrocycles and their analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1940417A4 *
SWANSON R.N. ET AL: "In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 35, no. 6, June 1991 (1991-06-01), pages 1108 - 1111, XP003012680 *

Also Published As

Publication number Publication date
AU2006304868A1 (en) 2007-04-26
CN101340919B (en) 2011-12-07
KR20080064177A (en) 2008-07-08
CN102503994A (en) 2012-06-20
CN101340919A (en) 2009-01-07
CA2626698C (en) 2015-12-01
HK1126410A1 (en) 2009-09-04
KR101399621B1 (en) 2014-06-18
JP2009512691A (en) 2009-03-26
WO2007048059A2 (en) 2007-04-26
CA2626698A1 (en) 2007-04-26
EP1940417A2 (en) 2008-07-09
EP1940417A4 (en) 2010-07-07
AU2006304868B2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
WO2007048059A3 (en) Method of treating clostridium difficile-associated diarrhea
WO2014086750A3 (en) Composition comprising a biological control agent and an insecticide
WO2007039313A3 (en) Probiotic enterococci for improved immunity
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2006047756A3 (en) Substituted tetracycline compounds
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
BRPI0717219A2 (en) "immunogenic composition, method for treating or preventing disease, and use of an immunogenic composition."
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2011130650A3 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2007022344A3 (en) Methods and compositions for the preventioin and treatment of kidney disease
WO2007140312A3 (en) Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
WO2006138059A3 (en) Treatment of autoimmune disorders with a neurotoxin
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2006116169A3 (en) Methods for modulating bladder function
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2008030883A3 (en) Treatment of cancer
TW200734344A (en) Antibacterial agents
WO2014086764A3 (en) Composition comprising a biological control agent and a fungicide
EA201000383A1 (en) METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY INTRODUCTION OF ORITAWAN
DE602007013922D1 (en) ANTIBIOTIC AND ANTIMICROBIAL ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680047986.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008536608

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2626698

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006304868

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2006826544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006826544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1833/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006304868

Country of ref document: AU

Date of ref document: 20061023

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087012193

Country of ref document: KR